Skip to content

Northern Trust invests in Essentia Analytics

Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust (Nasdaq: NTRS) has reached an agreement to take an equity stake in Essentia Analytics, Ltd., … Continued

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Calculus strengthens Investor Relations team

Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the tax efficient third-party manager panel and driving distribution through product specialist support to Wealth Managers … Continued

Calculus’ 22nd EIS Fund open for subscription

Calculus EIS Fund was the first approved EIS Fund on the market 22nd iteration of the Fund launched this week The last 18 months have seen 10 exits across the EIS Funds including 6x return for ActiveOps Calculus Capital are delighted to launch the Calculus EIS Fund offering an opportunity to invest in entrepreneurial businesses … Continued

Arecor Announce US Phase 1 Trial

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes. The IND supports a Phase I clinical trial in … Continued